At CBI, we offer a number of ARDS type models including oleic acid-induced ARDS, LPS-induced pulmonary inflammation, albumin-induced immune mediated pulmonary inflammation, murine sarcoidiosis- Propionibacterium acne-induced hypersensitivity or granulomatous pneumonia, pulmonary hyperoxygenation, aspergillus pneumonia, murine Farmer’s Lung- Saccharopolyspora rectivirgula-induced hypersensitivity pneumonitis, cecal ligation and puncture and oxygen-induced pulmonary bronchodysplasia. All of these models offer good correlation with the lesions in COVID-induced ARDs. We offer customized and innovative pulmonary models. With our models, assessments include respiratory signs, oxygenation, cytokine assays, BAL assessment, histopathology and immunohistochemistry as part of a plan to assess the potential activity of test articles for treatment of COVID-19 ARDS. Check out our Covid ARDS-19 Powerpoint Presentation.
This is an emerging, rapidly evolving situation and Comparative Biosciences, Inc. will provide updated information as it becomes available, in addition to updated guidance.
CBI HAS THE EXPERIENCE AND CAPABILITIES TO CONDUCT PRECLINICAL MODELS OF ARDS TO ASSESS POTENTIAL THERAPIES – Dr Carol Meschter
– Contact Comparative Biosciences, Inc. to discuss a scientific study program for COVID ARDS Studies and Services.
Contact Jonathan A. Geller, MS Business Development Manager